Genenta Science S.p.A. American Depositary Shares (GNTA)

Genenta Science, a biotech company, has secured €20 million ($21.9M) in financing to expand its pipeline, including advancing its Temferon™ product candidate for metastatic Renal Cell Carcinoma. The company's brain tumor trial is also showing promising survival rates.

The article discusses recent advancements in cancer research and treatment, including promising results from clinical trials of various cancer therapies developed by companies like Oncolytics Biotech, Celcuity, Genenta Science, Sellas Life Sciences, and Amgen.